Organic compounds -- part of the class 532-570 series – Organic compounds – Carboxylic acid esters
Patent
1997-12-05
2000-03-07
Geist, Gary
Organic compounds -- part of the class 532-570 series
Organic compounds
Carboxylic acid esters
514506, 436 74, 436 63, 436 64, 436 96, 435 29, 435 34, 424 96, C07C22900, A61K 31195
Patent
active
060342676
DESCRIPTION:
BRIEF SUMMARY
The present invention relates to derivatives of 5-aminolevulinic acid (ALA) and in particular to esters of ALA for use as photosensitizing agents in photochemotherapy or diagnosis.
Photochemotherapy, or photodynamic therapy (PDT) as it is also known, is a recently up-coming technique for the treatment of various abnormalities or disorders of the skin or other epithelial organs or mucosa, especially cancers or pre-cancerous lesions, as well as certain non-malignant lesions for example skin complaints such as psoriasis. Photochemotherapy involves the application of photosensitizing (photochemotherapeutic) agents to the affected area of the body, followed by exposure to photoactivating light in order to activate the photosensitizing agents and convert them into cytotoxic form, whereby the affected cells are killed or their proliferative potential diminished.
A range of photosensitizing agents are known, including notably the psoralens, the porphyrins, the chlorins and the phthalocyanins. Such drugs become toxic when exposed to light.
Photosensitizing drugs may exert their effects by a variety of mechanisms, directly or indirectly. Thus for example, certain photosensitizers become directly toxic when activated by light, whereas others act to generate toxic species, e.g. oxidising agents such as singlet oxygen or other oxygen-derived free radicals, which are extremely destructive to cellular material and biomolecules such as lipids, proteins and nucleic acids. Psoralens are an example of directly acting photosensitizers; upon exposure to light they form adducts and cross-links between the two strands of DNA molecules, thereby inhibiting DNA synthesis. The unfortunate risk with this therapy is that unwanted mutagenic and carcinogenic side effects may occur.
This disadvantage may be avoided by selecting photosensitizers with an alternative, indirect mode of action. For example porphyrins, which act indirectly by generation of toxic oxygen species, have no mutagenic side effects and represent more favourable candidates for photochemotherapy. Porphyrins are naturally occurring precursors in the synthesis of heme. In particular, heme is produced when iron (Fe.sup.3+) is incorporated in protoporphyrin IX (Pp) by the action of the enzyme ferrochelatase. Pp is an extremely potent photosensitizer, whereas heme has no photosensitizing effect.
One such porphyrin-based drug, Photofrin, has recently been approved as a photosensitizer in the therapy of certain cancers. The main disadvantage is that since it must be administered parenterally, generally intravenously, cause photosensitization of the skin which may last for several weeks following i.v. injection. Photofrin consists of large oligomers of porphyrin and it does not readily penetrate the skin when applied topically. Similar problems exist with other porphyrin-based photosensitizers such as the so-called "hematoporphyrin derivative" (Hpd) which has also been reported for use in cancer photochemotherapy (see for example S. Dougherty. J. Natl. Cancer Ins., 1974, 52; 1333; Kelly and Snell, J. Urol, 1976, 115: 150). Hpd is a complex mixture obtained by treating haematoporphyrin with acetic and sulphuric acids, after which the acetylated product is dissolved with alkali.
To overcome these problems, precursors of Pp have been investigated for photochemotherapeutic potential. In particular the Pp precursor 5-aminolevulinic acid (ALA) has been investigated as a photochemotherapeutic agent for certain skin cancers. ALA, which is formed from succinyl CoA and glycine in the first step of heme synthesis, is to a limited extent able to penetrate the skin and lead to a localised build-up of Pp; since the action of ferrochelatase (the metallating enzyme) is the rate limiting step in heme synthesis, an excess of ALA leads to accumulation of Pp, the photosensitizing agent. Thus, by applying ALA topically to skin tumours, and then after several hours exposing the tumours to light, a beneficial photochemotherapeutic effect may be obtained (see for example WO91/01727). Since the skin c
REFERENCES:
patent: 4575515 (1986-03-01), Sandborn
patent: 5079262 (1992-01-01), Kennedy et al.
patent: 5211938 (1993-05-01), Kennedy et al.
patent: 5219878 (1993-06-01), Ringuet et al.
patent: 5234940 (1993-08-01), Kennedy et al.
patent: 5422093 (1995-06-01), Kennedy et al.
Davies, A. G.; Organic Peroxides; Butterworth and Co. London, p. 196, 1961.
Cotton, F. A. et .al;. Advanced Inorganic Chemistry, 5th ed. Wiley, New York; pp. 305-309, 382-386, 1988.
Salerni, O. L. et al.; J. Chem Soc. (C); p. 1400, 1968.
Ariens, E. J.; Drug Design; Academic Press; New York; pp. 8-11, 70-71, 1971.
Morrison, R. T. et al.; Organic Chemistry 3rd Ed.; Allyn and Bacon; Boston; pp. 631,666, 668-669, 673, 1973.
Gawell, L. et al.; Acta Chemica Scandinavica; 43; p. 478, 479, 1989.
Schulz, G. et al.; Chem. Ber.; 113 (2); p. 772, 1980.
Database Xfire, entries 3060978, 5347132, 5499790, 5620924, 5633390, 5991317 and 6517740, Beilstein.
Chemical Abstracts, 16, Abstract of Japanese Patent Application No. JP900287712 (Haruhiko), published Jan. 14, 1992, from, (Apr. 16, 1992).
Dougherty, T.J., "Activated Dyes as Antitumor Agents", Journal of the National Cancer Institute, 52, 1333-1336, (Apr. 1974).
Kelly, J.F., et al., "Hematoporphyrin Derivative: A Possible Aid in the Diagnosis and Therapy of Carcinoma of the Bladder", The Journal of Urology, 115, Copyrighted 1976 by The Williams & Wilkins Co., 150-151, (Feb.).
Kloek, J., et al., "Prodrugs of 5-Aminolevulinic Acid for Photodynamic Therapy", Photochemistry and Photobiology, 64(6), 994-1000, (1996).
Qian, P., et al., "A Comparison of Different Photosensitizing Dyes with Respect to Uptake C3H-Tumors and Tissues of Mice", Cancer Letters, 36, 1-10, (1987).
Bjorseth Alf
Gierskcky Karl E.
Moan Johan
Peng Qian
Steen Harald
Deemie Robert
Geist Gary
PhotoCure AS
LandOfFree
Esters of 5-aminolevulinic acid as photosensitizing agents in ph does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Esters of 5-aminolevulinic acid as photosensitizing agents in ph, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Esters of 5-aminolevulinic acid as photosensitizing agents in ph will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-364679